HOME >> BIOLOGY >> NEWS
Whitaker Foundation funds Washington University biomedical engineering facility

me a national leader in an important field that is bringing to the world breakthroughs in human health every day."

"We are extremely pleased to have the support of The Whitaker Foundation to build a world-class biomedical engineering department," stated Frank C.P. Yin, M.D., Ph.D., chair of the department and director of the university's Institute of Biological and Medical Engineering. (Yin also is Steven F. and Camilla T. Brauer Professor of Biomedical Engineering.) "We will be recruiting a mix of outstanding senior and junior faculty. Once the building and the new faculty are in place, we will be more than ready to meet the demand for biomedical engineering, which already is extremely popular with our students."

Christopher I. Byrnes, dean of the School of Engineering and Applied Sciences, said this high demand was anticipated early on in the planning for the 21st century. "The need for a strong biomedical engineering department was identified as one of the school's top priorities during our Project 21 planning process," Byrnes noted.

Recognizing the need to begin building a biomedical engineering center, the new department was introduced in the fall of 1997, with 50 freshman students expressing an interest in a major. This fall, nearly one-third of the 270 incoming engineering freshmen have declared an interest in the biomedical engineering major. Roughly half of the engineering students earning a bachelor's degree pursue a medical degree, with the other half going into industry or academia. The department currently enrolls 29 graduate students, 19 doctoral candidates and 10 master's degree students.

"The Biomedical Engineering department has been growing steadily, with the resulting growing pains," said Byrnes. "The Foundation's awards will transform the young department with limited space into a major center of research and teaching."

While the young department is small, with a core faculty of five full-time
'"/>

Contact: Tony Fitzpatrick
tony_fitzpatrick@aismail.wustl.edu
314-935-5272
Washington University in St. Louis
4-Nov-1999


Page: 1 2 3 4

Related biology news :

1. Whitaker Foundation to phase out grant programs
2. UC Davis biomedical engineering department awarded $12 million by Whitaker Foundation
3. Whitaker makes largest individual grants ever totaling more than $30 million
4. Whitaker Foundation To Fund AAAS Science Journalism Awards Through 2001
5. Whitaker Awards $6.8 Million For Biomedical Engineering Education
6. Brown ecologist garners major National Science Foundation grant
7. APS Foundation names student travel award recipients
8. Institute for OneWorld Health receives Gates Foundation grant
9. National Parkinson Foundation designates UNC as Center of Excellence
10. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
11. Leslie Ann Schiff wins 2004 Carski Foundation Award

Post Your Comments:
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: